本帖最后由 老马 于 2013-3-13 13:43 编辑
! }4 I+ i& k, I* i+ f- e6 C+ M0 z9 }' @) [
健择(吉西他滨)+顺铂+阿瓦斯汀
: v: t6 a' E9 ^/ g4 B2 { | Gemzar +Cisplatin + Avastin
3 a: ` t/ P2 x z8 Bhttp://annonc.oxfordjournals.org/content/21/9/1804.full
" \5 R! g) _7 E6 uOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ' Y0 y4 s$ j5 a
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. , A! v3 a- [( C' o6 x
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 2 q+ s; ]; r. P! P' r$ E4 @
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 835)
0 s2 Q% C C$ L; T) c) U
华为网盘附件:4 D: h# ^! D' F9 R& p
【华为网盘】ava.JPG
) I0 }$ n+ p' H% A2 H |